Market Insight from

Will the Early Access to Medicines Scheme speed up patient access to innovative drugs?

Of the Early Access to Medicines Scheme approvals given by the UK's Medicines and Healthcare Regulatory Authority (MHRA), almost half are for drugs already authorised in other markets.

The MHRA Early Access to Medicines Scheme (EAMS) is a two-step voluntary process through which companies can apply for a drug to address an unmet medical need, allowing UK patients access to the treatment.

The first step is th MHRA’s designation of a Promising Innovative Medicine (PIM) as an early positive indicator that the drug is intending to treat, diagnose or prevent a life-threatening or seriously debilitating illness.

US biopharma company Global Blood Therapeutics’ drug voxelotor, already approved in the US as Oxbryta, was the first sickle cell drug to receive PIM designation on 14 June. Since the scheme was launched in 2014, however, has there been significant progress in getting innovative drugs to the UK market?

GlobalData’s Pharma Intelligence Centre Drugs database covers drugs that have received PIM designations. These are given to drugs that have completed Phase III trials or, in exceptional circumstances, Phase II trials and flags to investors on drugs’ potential towards getting regulatory approval for the indication of interest.

The second step is the EAMS Scientific Opinion assessment, which is only issued once a drug meets the EAMS safety criteria and with a positive benefit, namely risk ratio. Only then can the National Health Service (NHS) commission the free supply of the drug from the company for patients.

The UK has almost half of its pharmaceutical companies receiving PIM/EAMS status, at 48%, with the US receiving 24% and the remaining companies predominately coming from Europe, according to GlobalData’s Pharma Intelligence Centre Drugs database (Figure 1).

Out of the total number of companies that have received PIM/EAMS status, 46% are for drugs that have already received marketing authorisation in other markets. This begs the question, therefore, of how much progress this scheme will contribute to getting novel drugs to market.

For example, Pfizer received PIM designation last October for abrocitinib in Phase III in the UK for the treatment of severe atopic dermatitis. The drug was then issued a positive EAMS scientific opinion in February.

Sanofi also received PIM designation last October for avalglucosidase alfa in Phase III in the UK for Pompe disease, and the drug was issued a positive EAMS scientific opinion in March.

According to a survey of biopharma companies interviewed in GlobalData’s Brexit and the Healthcare Industry report on 27 April, 66% of the companies interviewed indicated that the regulatory implications of the UK leaving the European Economic Area EEA remained the highest factor impacting healthcare after Brexit.

With the UK no longer being part of the EU’s regulatory system, the additional burden of clinical trials and impact on the market authorisation of drugs will need to be closely watched.

For pharmaceutical industry data, comment and analysis, visit GlobalData's Pharmaceuticals Intelligence Centre.

Go to article: Home | Waive goodbye to vaccine patentsGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: DatwylerGo to article: Datwyler Company InsightGo to article: LabcorpGo to article: Biesterfeld Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Dr. Paul LohmannGo to article: ButterworthGo to article: SkyepharmaGo to article: BaxterGo to article: CommentGo to article: Speeding up patient access to innovative drugsGo to article: The competitive landscape of neoantigen-targeting therapeutics in oncologyGo to article: Bacterial “cell factories”: an eco-friendly approach to chemical productionGo to article: MDR set to transform how MedTech firms approach content managementGo to article: PerkinElmerGo to article: NiproGo to article: NiproGo to article: In DepthGo to article: Should UK children be vaccinated against chickenpox?Go to article: Fighting India’s ‘black fungus’ epidemicGo to article: What could a vaccine patent waiver mean for pharma manufacturing? Go to article: Algae proteins: a vision of the futureGo to article: A brief history of ALS awareness and its sparse treatments Go to article: Ferring draws closer to a microbiome breakthroughGo to article: The Solubility companyGo to article: Myonex Go to article: Owen MumfordGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue